Many neuroendocrine tumors can be successfully treated with surgery and chemotherapy, especially if the tumor is localized and has not spread to the lymph nodes or other organs in the body.
We aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Case numbers are resurging in parts of the world where the COVID-19 pandemic was waning, falling in places that saw huge surges recently, and just beginning to rise in previously little-impacted parts of the globe.
Studying and analyzing the impact of Coronavirus COVID-19 on the Neuroendocrine Tumor Treatment industry, the report provide in-depth analysis and professtional advices on how to face the post COIVD-19 period.
Market Segment by Product Type
Everolimus
Sunitinib
Lu-Dotatate
Lanreotide
Octreotide
Market Segment by Product Application
Hospitals
Clinic
Others
Finally, the report provides detailed profile and data information analysis of leading company.
Exelixis, Inc.
Advanced Accelerator Applications
Dauntless Pharmaceuticals, Inc.
Hutchinson Medipharma Limited
Ispen
Novartis AG
Progenics Pharmaceuticals, Inc.
Tarveda Therapeutics
Insights and Tools:
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.
Product values and regional markets are estimated by market analyst, data analyst and people from related industry, based on companys' revenue and applications market respectively.
The data sources include but not limited to reports of companys,international organizations and governments, MMI market surveys,and related industry news.
Analyses of global market trends, with historical data, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
The market research includes historical and forecast data from like demand, application details, price trends, and company shares by geography, especially focuses on the key regions like United States, European Union, China, and other regions.
In addition, the report provides insight into main drivers,challenges,opportunities and risk of the market and strategies of suppliers. Key players are profiled as well with their market shares in the global market discussed.
Research Objectives
1.To study and analyze the global Neuroendocrine Tumor Treatment consumption (value) by key regions/countries, product type and application, history data from 2016 to 2020, and forecast to 2026.
2.To understand the structure of Neuroendocrine Tumor Treatment market by identifying its various subsegments.
3.Focuses on the key global Neuroendocrine Tumor Treatment manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
4.To analyze the Neuroendocrine Tumor Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
6.To project the consumption of Neuroendocrine Tumor Treatment submarkets, with respect to key regions (along with their respective key countries).
7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
8.To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
Global Neuroendocrine Tumor Treatment Market Research Report 2021, Forecast to 2026
1 Market Study Overview
1.1 Study Objectives
1.2 Neuroendocrine Tumor Treatment Introduce
1.3 Combined with the Analysis of Macroeconomic Indicators
1.4 Brief Description of Research methods
1.5 Market Breakdown and Data Triangulation
2 Global Trend Summary
2.1 Neuroendocrine Tumor Treatment Segment by Type
2.1.1 Everolimus
2.1.2 Sunitinib
2.1.3 Lu-Dotatate
2.1.4 Lanreotide
2.1.5 Octreotide
2.2 Market Analysis by Application
2.2.1 Hospitals
2.2.2 Clinic
2.2.3 Others
2.3 Global Neuroendocrine Tumor Treatment Market Comparison by Regions (2016-2026)
2.3.1 Global Neuroendocrine Tumor Treatment Market Size (2016-2026)
2.3.2 North America Neuroendocrine Tumor Treatment Status and Prospect (2016-2026)
2.3.3 Europe Neuroendocrine Tumor Treatment Status and Prospect (2016-2026)
2.3.4 China Neuroendocrine Tumor Treatment Status and Prospect (2016-2026)
2.3.5 Japan Neuroendocrine Tumor Treatment Status and Prospect (2016-2026)
2.3.6 Southeast Asia Neuroendocrine Tumor Treatment Status and Prospect (2016-2026)
2.4 Basic Product Information
2.4.1 Basic Product Information & Technology Development History
2.4.2 Product Manufacturing Process
2.4.3 Interview with Major Market Participants
2.4.4 High-end Market Analysis and Forecast
2.5 Coronavirus Disease 2019 (Covid-19): Neuroendocrine Tumor Treatment Industry Impact
2.5.1 Neuroendocrine Tumor Treatment Business Impact Assessment - Covid-19
2.5.2 Market Trends and Neuroendocrine Tumor Treatment Potential Opportunities in the COVID-19 Landscape
2.5.3 Measures / Proposal against Covid-19
3 Competition by Manufacturer
3.1 Global Neuroendocrine Tumor Treatment Sales and Market Share by Manufacturer (2016-2021)
3.2 Global Neuroendocrine Tumor Treatment Revenue and Market Share by Manufacturer (2016-2021)
3.3 Global Neuroendocrine Tumor Treatment Industry Concentration Ratio (CR5 and HHI)
3.4 Top 5 Neuroendocrine Tumor Treatment Manufacturer Market Share
3.5 Top 10 Neuroendocrine Tumor Treatment Manufacturer Market Share
3.6 Date of Key Manufacturers Enter into Neuroendocrine Tumor Treatment Market
3.7 Key Manufacturers Neuroendocrine Tumor Treatment Key Manufacturers
3.8 Mergers & Acquisitions Planning
4 Analysis of Neuroendocrine Tumor Treatment Industry Key Manufacturers
4.1 Exelixis, Inc.
4.1.1 Compan Detail
4.1.2 Exelixis, Inc. Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.1.3 Exelixis, Inc. 139 Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.1.4 Main Business Overview
4.1.5 Exelixis, Inc. News
4.2 Advanced Accelerator Applications
4.2.1 Compan Detail
4.2.2 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.2.4 Main Business Overview
4.2.5 Exelixis, Inc. News
4.3 Dauntless Pharmaceuticals, Inc.
4.3.1 Compan Detail
4.3.2 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.3.4 Main Business Overview
4.3.5 Dauntless Pharmaceuticals, Inc. News
4.4 Hutchinson Medipharma Limited
4.4.1 Compan Detail
4.4.2 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.4.4 Main Business Overview
4.4.5 Hutchinson Medipharma Limited News
4.5 Ispen
4.5.1 Compan Detail
4.5.2 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.5.3 Ispen Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.5.4 Main Business Overview
4.5.5 Ispen News
4.6 Novartis AG
4.6.1 Compan Detail
4.6.2 Novartis AG Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.6.3 Novartis AG Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.6.4 Main Business Overview
4.6.5 Novartis AG News
4.7 Progenics Pharmaceuticals, Inc.
4.7.1 Compan Detail
4.7.2 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.7.4 Main Business Overview
4.7.4 Main Business Overview
4.8 Tarveda Therapeutics
4.8.1 Compan Detail
4.8.2 Tarveda Therapeutics Neuroendocrine Tumor Treatment Product Introduction, Application and Specification
4.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Sales, Price, Cost, Gross Margin, and Revenue (2016-2021)
4.8.4 Main Business Overview
4.8.5 Tarveda Therapeutics News
5 Global Neuroendocrine Tumor Treatment Market Segment by Big Type
5.1 Global Neuroendocrine Tumor Treatment Revenue, Sales and Market Share by Big Type (2016-2021)
5.1.1 Global Neuroendocrine Tumor Treatment Sales and Market Share by Big Type (2016-2021)
5.1.2 Global Neuroendocrine Tumor Treatment Revenue and Market Share by Big Type (2016-2021)
5.2 Everolimus Sales Growth Rate and Price
5.2.1 Global Everolimus Sales Growth Rate (2016-2021)
5.2.2 Global Everolimus Price (2016-2021)
5.3 Sunitinib Sales Growth Rate and Price
5.3.1 Global Sunitinib Sales Growth Rate (2016-2021)
5.3.2 Global Sunitinib Price (2016-2021)
5.4 Lu-Dotatate Sales Growth Rate and Price
5.4.1 Global Lu-Dotatate Sales Growth Rate (2016-2021)
5.4.2 Global Lu-Dotatate Price (2016-2021)
5.5 Lanreotide Sales Growth Rate and Price
5.5.1 Global Lanreotide Sales Growth Rate (2016-2021)
5.5.2 Global Lanreotide Price (2016-2021)
5.6 Octreotide Sales Growth Rate and Price
5.6.1 Global Octreotide Sales Growth Rate (2016-2021)
5.6.2 Global Octreotide Price (2016-2021)
6 Global Neuroendocrine Tumor Treatment Market Segment by Big Application
6.1 Global Neuroendocrine Tumor Treatment Sales Market Share by Big Application (2016-2021)
6.2 Hospitals Sales Growth Rate (2016-2021)
6.3 Clinic Sales Growth Rate (2016-2021)
6.4 Others Sales Growth Rate (2016-2021)
7 Global Neuroendocrine Tumor Treatment Forecast
7.1 Global Neuroendocrine Tumor Treatment Revenue, Sales and Growth Rate (2021-2026)
7.2 Neuroendocrine Tumor Treatment Market Forecast by Regions (2021-2026)
7.2.1 North America Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
7.2.2 Europe Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
7.2.3 China Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
7.2.4 Japan Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
7.2.5 Southeast Asia Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
7.2.6 Other Regions Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
7.3 Neuroendocrine Tumor Treatment Market Forecast by Type (2021-2026)
7.3.1 Global Neuroendocrine Tumor Treatment Sales Forecast by Type (2021-2026)
7.3.2 Global Neuroendocrine Tumor Treatment Market Share Forecast by Type (2021-2026)
7.4 Neuroendocrine Tumor Treatment Market Forecast by Application (2021-2026)
7.4.1 Global Neuroendocrine Tumor Treatment Sales Forecast by Application (2021-2026)
7.4.2 Global Neuroendocrine Tumor Treatment Market Share Forecast by Application (2021-2026)
8 Market Analysis
8.1.1 Market Overview
8.1.2 Market Opportunities
8.1.3 Market Risk
8.1.4 Market Driving Force
8.1.5 Porter's Five Forces Analysis
8.1.6 SWOT Analysis
9 Neuroendocrine Tumor Treatment Related Market Analysis
9.1 Upstream Analysis
9.1.1 Macro Analysis of Upstream Markets
9.1.2 Key Players in Upstream Markets
9.1.3 Upstream Market Trend Analysis
9.1.4 Neuroendocrine Tumor Treatment Manufacturing Cost Analysis
9.2 Downstream Market Analysis
9.2.1 Macro Analysis of Down Markets
9.2.2 Key Players in Down Markets
9.2.3 Downstream Market Trend Analysis
9.2.4 Sales Channel, Distributors, Traders and Dealers
10 Research Findings and Conclusion
List of Tables and Figures
Figure Product Picture Neuroendocrine Tumor Treatment
Figure Market Concentration Ratio and Market Maturity Analysis of Neuroendocrine Tumor Treatment
Figure Bottom-up and Top-down Approaches for This Report
Figure Part of Our External Database
Figure Part of Our External Database
Figure Key Executives Interviewed
Table Global Neuroendocrine Tumor Treatment Market Size by Big Type
Figure Global Market Share of Neuroendocrine Tumor Treatment by Big Type in 2020
Figure Everolimus Picture (2016-2021)
Figure Sunitinib Picture (2016-2021)
Figure Lu-Dotatate Picture (2016-2021)
Figure Lanreotide Picture (2016-2021)
Global Neuroendocrine Tumor Treatment Market Size by Big Application
Table Global Neuroendocrine Tumor Treatment Market Size by Application
Figure Global Neuroendocrine Tumor Treatment Market Share by Big Application in 2020
Figure Hospitals Picture
Figure Clinic Picture
Figure Others Picture
Table Global Neuroendocrine Tumor Treatment Comparison by Regions (M USD) (2016-2026)
Figure Global Neuroendocrine Tumor Treatment Market Size (Million US$) (2016-2026)
Figure North America Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate (2016-2026)
Figure Europe Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate (2016-2026)
Figure China Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate (2016-2026)
Figure Japan Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate (2016-2026)
Figure Southeast Asia Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate (2016-2026)
Table Business Impact Assessment - Covid-19
Table Market Trends and Neuroendocrine Tumor Treatment Potential Opportunities in the COVID-19 Landscape
Table Measures / Proposal against Covid-19
Table Global Neuroendocrine Tumor Treatment Sales by Manufacturer (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Sales Market Share by Manufacturer in 2020
Table Global Neuroendocrine Tumor Treatment Revenue by Manufacturer (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Revenue Market Share by Manufacturer in 2020
Table Global Neuroendocrine Tumor Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Figure Top 5 Neuroendocrine Tumor Treatment Manufacturer (Revenue) Market Share in 2020
Figure Top 10 Neuroendocrine Tumor Treatment Manufacturer (Revenue) Market Share in 2020
Table Date of Key Manufacturers Enter into Neuroendocrine Tumor Treatment Market
Table Key Manufacturers Neuroendocrine Tumor Treatment Product Type
Table Mergers & Acquisitions Planning
Table Exelixis, Inc. Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Exelixis, Inc.
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company One 2016-2021
Table Company One Main Business
Table Company One Recent Development
Table Advanced Accelerator Applications Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Advanced Accelerator Applications
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Advanced Accelerator Applications Recent Development
Table Dauntless Pharmaceuticals, Inc. Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Dauntless Pharmaceuticals, Inc.
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Dauntless Pharmaceuticals, Inc. Main Business
Table Dauntless Pharmaceuticals, Inc. Recent Development
Table Hutchinson Medipharma Limited Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Hutchinson Medipharma Limited
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Hutchinson Medipharma Limited Main Business
Table Hutchinson Medipharma Limited Recent Development
Table Hutchinson Medipharma Limited Main Business
Table Hutchinson Medipharma Limited Recent Development
Table Ispen Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Ispen
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Ispen Main Business
Table Ispen Recent Development
Table Novartis AG Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Novartis AG
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Novartis AG Main Business
Table Novartis AG Recent Development
Table Progenics Pharmaceuticals, Inc. Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Progenics Pharmaceuticals, Inc.
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Progenics Pharmaceuticals, Inc. Main Business
Table Progenics Pharmaceuticals, Inc. Recent Development
Table Tarveda Therapeutics Company Profile
Table Neuroendocrine Tumor Treatment Product Introduction, Application and Specification of Tarveda Therapeutics
Table Neuroendocrine Tumor Treatment Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2016-2021
Table Tarveda Therapeutics Main Business
Table Tarveda Therapeutics Recent Development
Figure Global Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Revenue and Growth Rate (2016-2021)
Table Global Neuroendocrine Tumor Treatment Sales by Regions (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Sales Market Share by Regions in 2020
Table Global Neuroendocrine Tumor Treatment Revenue by Regions (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Revenue Market Share by Regions in 2020
Figure North America Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Figure Europe Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Figure China Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Figure Japan Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Figure Southeast Asia Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Figure Other Regions Neuroendocrine Tumor Treatment Sales and Growth Rate (2016-2021)
Table Global Neuroendocrine Tumor Treatment Sales by Big Type (2016-2021)
Table Global Neuroendocrine Tumor Treatment Sales Market Share by Big Type (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Sales Market Share by Big Type in 2019
Table Global Neuroendocrine Tumor Treatment Revenue by Big Type (2016-2021)
Table Global Neuroendocrine Tumor Treatment Revenue Market Share by Big Type (2016-2021)
Table Global Neuroendocrine Tumor Treatment Revenue Market Share by Big Type in 2019
Figure Global Everolimus Sales Growth Rate (2016-2021)
Figure Global Everolimus Price (2016-2021)
Figure Global Sunitinib Sales Growth Rate (2016-2021)
Figure Global Sunitinib Price (2016-2021)
Figure Global Lu-Dotatate Sales Growth Rate (2016-2021)
Figure Global Lu-Dotatate Price (2016-2021)
Figure Global Lanreotide Sales Growth Rate (2016-2021)
Figure Global Lanreotide Price (2016-2021)
Table Global Neuroendocrine Tumor Treatment Sales by Big Application (2016-2021)
Table Global Neuroendocrine Tumor Treatment Sales Market Share by Big Application (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Sales Market Share by Big Application in 2019
Figure Global Hospitals Sales Growth Rate (2016-2021)
Figure Global Clinic Sales Growth Rate (2016-2021)
Figure Global Others Sales Growth Rate (2016-2021)
Figure Global Neuroendocrine Tumor Treatment Sales and Growth Rate (2021-2026)
Figure Global Neuroendocrine Tumor Treatment Revenue and Growth Rate (2021-2026)
Table Global Neuroendocrine Tumor Treatment Sales Forecast by Regions (2021-2026)
Table Global Neuroendocrine Tumor Treatment Market Share Forecast by Regions (2021-2026)
Figure North America Sales Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
Figure Europe Sales Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
Figure China Sales Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
Figure Japan Sales Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
Figure Southeast Asia Sales Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
Figure Other Regions Sales Neuroendocrine Tumor Treatment Market Forecast (2021-2026)
Table Global Neuroendocrine Tumor Treatment Sales Forecast by Type (2021-2026)
Table Global Neuroendocrine Tumor Treatment Market Share Forecast by Type (2021-2026)
Table Global Neuroendocrine Tumor Treatment Sales Forecast by Application (2021-2026)
Table Global Neuroendocrine Tumor Treatment Market Share Forecast by Application (2021-2026)
Table Market Opportunities in Next Few Years
Table Market Risks Analysis
Table Market Drivers
Figure Porter's Five Forces Analysis
Table Macro Analysis of Upstream Markets
Table Key Players in Upstream Markets
Table Key Players of Upstream Markets
Table Key Raw Materials
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neuroendocrine Tumor Treatment
Table Macro Analysis of Down Markets
Table Key Players in Down Markets
Table Key Players of Downstream Markets
Figure Sales Channel
Figure North America Neuroendocrine Tumor Treatment Sales (K Units) Growth Rate Forecast (2020-2025)
Figure North America Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate Forecast (2020-2025)
Figure Europe Neuroendocrine Tumor Treatment Sales (K Units) Growth Rate Forecast (2020-2025)
Figure Europe Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate Forecast (2020-2025)
Figure Japan Neuroendocrine Tumor Treatment Production (K Units) Growth Rate Forecast (2020-2025)
Figure Japan Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate Forecast (2020-2025)
Figure China Neuroendocrine Tumor Treatment Production (K Units) Growth Rate Forecast (2020-2025)
Figure China Neuroendocrine Tumor Treatment Revenue (Million US$) Growth Rate Forecast (2020-2025)
Figure Methodology/Research Approach
Figure Market Size Estimation
Figure Author List
Exelixis, Inc.
Advanced Accelerator Applications
Dauntless Pharmaceuticals, Inc.
Hutchinson Medipharma Limited
Ispen
Novartis AG